Chintan Patel, MD
Urology · Worcester, MANPI 1710240395
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,976 of the $31,439 with a category attached, or 76.3%. Microline Surgical Inc accounts for 68.7% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2024 at $11,028 and has fallen 57.6% since, to $4,677 in 2025. Among urology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $278.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microline Surgical Inc$22K
- Sanofi$3K
- Axonics, Inc.$1K
- Teleflex LLC$1K
- Procept Biorobotics Corporation$837
- Coloplast$768
- plus $3K from 24 others
What the payments were for
- Consulting fees$23,97676%
- Speaking & faculty fees$5502%
- Travel & lodging$6002%
- Food & beverage$5,75718%
- Education$5552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microline Surgical Inc | 7 | $21,600 |
| Sanofi | 4 | $2,730 |
| Axonics, Inc. | 11 | $1,075 |
| Teleflex LLC | 9 | $1,028 |
| Procept Biorobotics Corporation | 6 | $837 |
| Coloplast | 10 | $768 |
| Boston Scientific | 10 | $583 |
| Gyrus ACMI, Inc. | 1 | $550 |
| Neotract Inc. | 5 | $440 |
| Astellas Pharma US Inc | 12 | $318 |
| Koelis Inc. | 2 | $182 |
| Progenics Pharmaceuticals, Inc. | 3 | $151 |
| Avadel Specialty Pharmaceuticals, LLC | 2 | $147 |
| Dornier Medtech America, Inc | 1 | $127 |
| AstraZeneca | 5 | $119 |
| Laborie Medical Technologies Corp. | 1 | $108 |
| AbbVie | 4 | $97 |
| Endo Pharmaceuticals Inc. | 4 | $83 |
| Sumitomo Pharma America, Inc. | 1 | $77 |
| Photocure Inc | 1 | $66 |
| Merck | 3 | $66 |
| Calyxo, Inc. | 1 | $46 |
| Bayer | 2 | $45 |
| Astellas Pharma Global Development | 1 | $37 |
| Pfizer | 2 | $36 |
| Urogen Pharma, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $25 |
| Telix Pharmaceuticals | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEVTANA$2,581
- UroLift$1,107
- Axonics$941
- AquaBeam Robotic System$837
- TITAN$603
- Bulkamid$524
- Dornier MedTech$127
- AMS$125
- Noctiva$118
- Optilume BPH Drug Coated Balloon Catheter$108
- REZUM$107
- PYLARIFY$100
How this compares
$31,439 in reported general payments places this provider in the 90th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 227 | $218,270 |
| Tamsulosin Hcl | 1,325 | $29,196 |
| Mirabegron ErMirabegron | 32 | $21,575 |
| GemtesaVibegron | 16 | $15,243 |
| Trospium Chloride ErTrospium Chloride | 45 | $11,265 |
| Oxybutynin Chloride ErOxybutynin Chloride | 182 | $6,359 |
| Finasteride | 287 | $4,203 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 106 | $2,553 |
| Estradiol | 29 | $2,028 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,655 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 92 | $1,079 |
| Bethanechol Chloride | 12 | $939 |
| Oxybutynin Chloride | 35 | $865 |
| Testosterone | 16 | $702 |
| Terazosin Hcl | 26 | $608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $318 | $218,270227 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $77 | $15,24316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 327 urology providers in Massachusetts.
Other urology in Worcester
- Matthew ChabotWorcester$54K
- George HaleblianWorcester$41K
- Bhalchandra ParulkarWorcester$39K
- Igor SorokinWorcester$11K
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.